NOVO NORDISK A/S |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 901.5 DKK | -1.25% |
|
-0.69% | +29.44% |
| 10:54am | Roche: share price stands out, Deutsche Bank in support | CF |
| 05-16 | Health Care Flat as Momentum Wanes -- Health Care Roundup | DJ |
Presenter SpeechKarsten Knudsen (Executives)Thank you. Welcome to the virtual Q1 Novo Nordisk ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
2024-08-07
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
912.9
DKK
Average target price
909.2
DKK
Spread / Average Target
-0.40%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +29.38% | 593B | |
| +32.06% | 694B | |
| -1.62% | 371B | |
| +19.80% | 331B | |
| +6.70% | 290B | |
| +14.17% | 239B | |
| -2.99% | 209B | |
| +10.05% | 209B | |
| +8.07% | 169B | |
| -0.52% | 164B |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- Transcript : Novo Nordisk A/S, Q1 2020 Earnings Call, May 07, 2020